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Platelet activating factor (PAF) is a potent inﬂammatory mediator produced by various renal cells and it is implicated in renal
pathology. The aim of this study is the characterization of remodeling lyso-PAF acetyltransferase, which is activated under inﬂam-
matory conditions, in human mesangial cell. Total membranes of mesangial cells were isolated and enzymatic activity and kinetic
parameters were determined by trichloroacetic acid precipitation method. The eﬀect of BSA, divalent cations, EDTA, and various
chemicals on the activity of lyso-PAF acetyltransferase was also studied. Various detergents were also tested for the solubilization
of the enzyme and only glycerol did not aﬀect its activity. Partial puriﬁcation of solubilized enzyme preparations of human kidney
tissue and mesangial cells was performed on anion exchange column chromatography and native-PAGE electrophoresis and two
active fractions were detected.
INTRODUCTION
Platelet activating factor (PAF, 1-O-alkyl-2-acetyl-sn-
glycero-3-phosphocholine) [1] is a potent lipid mediator
with a wide variety of biological activities related to phys-
iological and pathological phenomena. Many diﬀerent
cells, including leukocytes, platelets, macrophages, neu-
trophils, lymphocytes, and endothelial cells can produce
PAF under appropriate stimuli [2]. Two enzymatic path-
ways of PAF biosynthesis have been described [3]. The
de novo pathway entails a speciﬁc stepwise sequence of
reactions starting with the acetylation of 1-O-alkyl-sn-
glycero-3-phosphate, which is an ether-linked metabolic
intermediate formed soon after the ether bond is created.
In contrast, the remodeling pathway involves a structural
modiﬁcation of preexisting ether-linked phospholipids
that serve as structural components of membranes [3]. It
is believed that the remodeling route plays a crucial role in
inﬂammatory/hypersensitivity responses of cells whereas
the de novo reaction sequence appears to be of physiolog-
ical importance maintaining basal PAF levels in various
tissues and blood. The main enzyme for PAF degradation
is PAF-acetylhydrolase (PAF-AH) [4].
PAF in the kidney can be produced by both biosyn-
thetic routes either by inﬁltrating inﬂammatory cells or
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by intrinsic glomerular cells such as mesangial cells [5].
Mesangial cells account for 20%–25% of all glomerular
cells. They are localized in the centre of the glomeru-
lar tuft and they have very important physiological func-
tions including structural support of capillary net work,
participation in ﬁltration regulation, synthesis and se-
cretion of matrix, eicosanoids, growth factors, and cy-
tokines [6]. These cells are inﬂuenced by both autocrine
and paracrine activities of the above factors. Apart from
its physiological eﬀects, the PAF produced in kidney is
involved in the pathogenesis of renal damage [7, 8, 9].
PAF infusion into the renal artery of animals reduces
the glomerular ﬁltration rate and the renal blood ﬂow,
and increases proteinuria and glomerular permeability
[9]. Moreover, increased levels of PAF and PAF-like lipids
have been detected in experimental models of glomeru-
lonephritis while parallel administration of PAF antag-
onists prevented or reduced renal damage [10]. In vitro
experiments revealed that PAF has multiple actions in
glomerularcells,especiallyinmesangialcellssinceitstim-
ulates several signalling pathways [11], causes contraction
[5] and matrix production [12]. These observations are
supported by a limited number of clinical studies demon-
strating increased PAF in patients with primary glomeru-
lonephritis [13], IgA nephropathy [14], and membranous
nephropathy [15].
The study of the enzymes of PAF metabolism is of
great interest since they regulate PAF levels both intra-
cellularly and extracellularly. Many of the features of
progressive glomerular diseases share common biolog-
ical mechanisms with those of atherosclerosis. Among264 Elizabeth Fragopoulou et al 2005:5 (2005)
them, inﬂammation is dominant. The last step in the
remodeling pathway, which is activated under inﬂam-
matory conditions, is catalysed by the enzyme acetyl-
CoA:1-O-alkyl-sn-glycero-3-phosphocholine acetyltrans-
ferase (lyso-PAF AT) (EC 2.3.1.67) which transfers an
acetyl group in the sn-2 position of lyso-PAF. Lyso-
PAF AT occurs in the microsomal fraction of a vari-
ety of tissues [16] and blood cells [17, 18]. The sub-
strate speciﬁcity of the lyso-PAF AT is rather broad
since 1-acyl-2-lysoglycerophosphocholine, 1-alky-1enyl-
2lysoglycerophosphoethanolamine, and other analogues
serve as substrates. Similarly, short-chain acyl-CoAs (C2-
C6) can be used as substrates for the acetyltransferase
[19]. Calcium has been reported to be necessary for
the expression of lyso-PAF AT activity although con-
trasting evidence has been found [16, 20, 21]. Partial
puriﬁcation of the enzyme from rat spleen has been
reported. Electrophoresis of the partially puriﬁed en-
zyme after the incorporation of labelled PAF revealed
that the radioactivity was associated with a protein pos-
sessing a molecular mass of 29kd [22]. No subsequent
experiments with puriﬁed preparations of the enzyme
have been described, although solubilization of the en-
zyme with glycerol has been reported [23]. Lyso-PAF
AT seems to be activated/inactivated by a phosphoryla-
tion/dephosphorylation mechanism [24, 25, 26, 27, 28,
29].AMP-dependentproteinkinase,calciumcalmodulin-
dependent protein kinase, protein kinase C, and kinase
p38 seem to be involved in the phosphorylation of the en-
zyme.
PAF-AH as well as remodeling and de novo acetyl-
transferases have been previously characterized in cortex
and medulla from human kidney tissue by our labora-
tory [20, 30, 31]. Although PAF metabolism has been de-
scribed in mesangial cells [32, 33], as far as we know there
are no direct studies on PAF biosynthetic enzymes. In the
present study, remodeling lyso-PAF AT was identiﬁed and
characterized in human mesangial cell line while a partial
puriﬁcation on lyso-PAF AT from human kidney tissue
and human mesangial cells is reported.
MATERIAL AND METHODS
Materialsandinstrumentation
All centrifugations were performed in a Sorvall RC-
5B refrigerated superspeed centrifuge (Sigma) apart from
the centrifugation at 100000xg, which was performed in
a Heraeus-Christ, Omega 70000 ultracentrifuge (Hanau,
Germany). For the precipitation of the bovine serum al-
bumin (BSA) pellet, a Sigma 201M microcentrifuge was
used (Sigma, Saint Louis, Mo, USA). The separation of
proteinwasperformedat4◦ConanHPHPLCSeries1100
liquid chromatography model (Hewlett Packard, Wald-
bronn, German) equipped with a 100µL Rheodyne (7725
i) loop valve injector, a degasser G1322A, a quat gradi-
ent pump G1311A, and an HP UV spectrophotometer
G1314A as a detection system. The spectrophotometer
was connected to a Hewlett- Packard (Hewlett Packard,
Waldbronn, German) model HP-3395 integrator-plotter.
An anion exchange column has been used for the sep-
aration of proteins (Resource Q, Amersham-Pharmacia
Biotech AB).
Radioactivity was measured in a 1209 Rack Beta ﬂex-
ivial liquid scintillation counter (Pharmacia).
[H3]acetyl-CoA (speciﬁc activity 200mCi/mmol)
was obtained from ICN (Costa Mesa, Calif). Lyso-PAF
(1-O-hexadecyl-2-lyso-sn-glycero-3-phosphocholine)
and acetyl-CoA were purchased from Sigma Chemicals
Co. 2, 5-diphenyloxazole (PPO) and 1, 4-Bis(5-phenyl-2-
oxazolyl) benzene (POPOP) were purchased from BDH
C h e m i c a l s( D o r s e t ,U K ) .E l e c t r o p h o r e s i sr e a g e n t sw e r e
obtained from Bio-Rad (Hercules, Calif). RPMI 1640,
foetal-calf serum (FCS), and trypsin-EDTA were from
Gibco BRL (Paisley, UK) and all other reagents were from
Sigma Chemicals Co (Saint Louis, Mo).
Cellculture
An established stable human mesangial cell line
(HMC) was used in all the experiments (kindly do-
nated by Dr Z. Varghese, Royal Free and University Col-
lage Medical School, London, United Kingdom). HMCs
were immortalized by transfection with T-SV40 and H-
ras oncogene, retaining many of the morphological and
physiological features of normal human mesangial cells
[34]. The cells were cultured in medium containing
RPMI 1640, 5% FCS, glutamine (2mmol/L), penicillin
(105 unit/L), streptomycin (0.1g/L), amphotericin (2.5 ×
10−3 g/L), insulin-transferrin (5 × 10−3 g/L), and sodium
selenite (5 ×10−6 g/L).
Humankidneytissues
Human kidney tissues were obtained from nephrec-
tomizedpatientswithadenocarcinoma.Immediatelyafter
the nephrectomy, the kidneys were perfused with normal
saline and a speciment obtained of the apparently normal
parenchyma and placed immediately in cold saline. Sub-
sequently, all homogenization and subcellular fractiona-
tion procedures were completed in less than 3 hours.
Homogenisationofkidneytissuesandpreparation
ofsubcellularfractions
Homogenisation of mesangial cells or kidney samples
and preparation of subcellular fraction was carried out
by a modiﬁcation [20] of the method described by Leni-
han and Lee [25]. Brieﬂy, mesangial cells were cultured
in 75cm2 ﬂasks, the pellet of the cells was resuspended in
homogenisationbuﬀercontaining0.25Msucrose,10mM
EDTA, 5mM mercaptoethanol (MeEtOH), 50mM NaF,
50mMTris-HCl(pH7.4),andwerehomogenizedbyson-
ication.
Kidney tissues were rinsed with ice-cold 0.25M su-
crose, then minced and homogenized with six strokes
of a motor-driven Potter-Elvehjem homogeniser in ho-
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in the homogenisation buﬀer was 10%w/v. Further ho-
mogenisation of the tissue by sonication was followed. In
both cases, the homogenates were centrifuged at 500xg
for 10 minutes. The pellets were discarded, a small por-
tionofthesupernatantswaskeptforproteinandlyso-PAF
AT determination and the rest of them were centrifuged
at 100000xg for 1 hour. The resulting pellets, total mem-
branes (TM), were suspended in suspension buﬀer con-
taining 0.25M sucrose, 1mM DTT, 50mM Tris-HCl (pH
7.4)(5–10mgofprotein/mL).Allfractionswerealiquoted
a n ds t o r e da t−20◦C. All homogenization and fractiona-
tion procedures were taken place at 4◦C.
Lyso-PAFATactivityassay
Lyso-PAF AT activity was measured by the method of
trichloroacetic acid (TCA) previously described [20]. Un-
less stated otherwise, subcellular fractions of mesangial
cellsorkidneytissue,containing10–50µgoftotalprotein,
were incubated with 20µM of lyso-PAF and 200µMo f
[H3]-acetyl-CoA (100Bq/nmoL) for 30 minutes at 37◦C
in a ﬁnal volume of 200µL of 50mM Tris-HCl buﬀer (pH
7.4) containing 0.25mg/mL BSA. By the end of the in-
cubation time 0.2mg of BSA were added and the reac-
tion was stopped by the addition of cold TCA solution
9.6% ﬁnal concentration. The reaction mixture was kept
in ice for 30 minutes and centrifuged at 10000xg for 2
minutes. The supernatant was discarded and the pellet
containing the [H3]PAF bound to the denaturated BSA is
dissolved in the scintillation cocktail (dioxane-base) and
the radioactivity was determined by liquid scintillation
counting. Matching controls were run in the absence of
lyso-PAF in order to subtract the radioactivity of the en-
dogenously produced [H3]PAF.
Solubilizationofproteins
For the solubilization of the proteins, total mem-
branes fractions were suspended in Tris-HCl buﬀer pH
7.4w i t hd i ﬀerent detergents in various concentrations
(w.v.) and various ratios of detergent/protein (w.w.). The
mixture was kept in ice for 40 minutes and it was cen-
trifuged at 100000xg for 1 hour at 4◦C. The pellets were
resuspended in suspension buﬀer. Both supernatants and
resuspendspelletsweretestedforlyso-PAFATactivityand
their protein concentration was determined.
HPLCseparation
Supernatants were placed in two-compartment cen-
trifuge tubes containing membranes with cutoﬀ value of
10000Da and concentrated by centrifugation at 5000xg
for 5 hours at 4◦C. The remaining concentrates were re-
suspended in Tris-HCl pH 7.4 and centrifuged at 5000xg
for 2 hours at 4◦C for the removal of the excess glycerol.
The total volume of the sample after centrifugation was
50–200µL. The separation was carried out on an anion
exchange column. The elution system consisted of a lin-
ear gradient from, starting buﬀer containing 20mM Tris-
HCl pH 8.0t oe l u t i o nb u ﬀer containing 20mM Tris-HCl
and 0.5MK ClpH8.0i n2 5m i n u t e s .T h eﬂ o wr a t ew a s
0.8mL/min and UV detection was carried out at 280nm.
One-minute fractions were collected for 30 minutes.
ELECTROPHORESIS
Nondenaturing electrophoresis was carried out
by a method previously described by Laemmli [35],
in which SDS was replaced by the nondenaturing
3-[(3-cholamidopropyl)-dimethylammonio]-1-propane-
sulfonate (CHAPS) (10mM). Slab gels consisting of 12%
(w.v.) separating polyacrilamide gel in 1.5M Tris-HCl,
pH 8.8 were exposed to a constant 30mA (250V) for 4.5
h o u r sa t4 ◦C. The stacking gel was made up as a 4% (w.v.)
gel in 0.5M Tris-HCl pH 6.5. The pH of the electrophore-
sis buﬀer was 8.3. The samples were run in duplicate.
Upon completion of electrophoresis, the gel was divided
into two parts. The ﬁrst part was sliced into 0.4cm
horizontal strips, which were individually extracted with
0.5ml Tris-HCl pH 7.4, incubated, overnight at 4◦Ca n d
collected by centrifugation. The second part was stained
by Coomassie Blue. Molecular markers (phosphatase-β
97.4kd, bovine serum albumin 66.2kd,ovalbumin45kd,
carbonic anhydrolase 31kd, trypsin inhibitor 21.5kd)
were run in parallel with the samples.
Analyticalmethods
Protein was determined by the method of Bradford
[36].
Statisticalanalysis
Unless otherwise stated, data are expressed as mean
values ± SD. The linear or nonlinear regressions of en-
zymes kinetics were made using GraphPad Prism. In or-
der to compare the inﬂuence of several factors on enzyme
activity, t test for independent samples was performed on
the speciﬁc activities values. All analyses were done with
the Statistical Package for Social Sciences (SPSS, version
10.0, SPSS Inc, Chicago, Ill, USA). Diﬀerences were con-
sidered statistically signiﬁcant at the 5% level.
RESULTS
Lyso-PAFATactivityofHMCand
humankidneytissues
The speciﬁc activity of lyso-PAF AT was measured in
500xg (homogenate fractions) and 100000xg (cytoplas-
mic fractions) supernatants as well as at 100000xg pellets
(total membrane fractions) of mesangial cells or human
kidney tissue preparations. The results are shown in Table
1. Lyso-PAF AT activity was detected in the 100000xg
pellet. Heating of samples at 50◦Ca n d6 0 ◦C for 10 min-
utesresultedin85%and100%inactivationoftheexisting
enzyme activity, respectively. Lyso-PAF AT speciﬁc activ-
ity was reduced 40% after a 20-day storage at −20◦C. All
subsequent experiments were performed with total mem-
brane (TM) preparations.266 Elizabeth Fragopoulou et al 2005:5 (2005)
Table 1. Subcellular speciﬁc activity of lyso-PAF AT from human kidney tissue and mesangial cell preparations.
Lyso-PAF AT speciﬁc activity (nmol/min/mg)
Subcellular fraction Human kidney tissue (n = 10) Mesangial cells (n = 5)
500xg supernatant 0.663 ±0.18 1.43 ±0.030
100000xg supernatant nda nd
100000xg pellet 1.46 ±0.53 2.52 ±0.20
and: not detected.
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Figure 1.EﬀectofpHonlyso-PAFATspeciﬁcactivityofmesan-
gial cells: TM fractions of HMC 0.23mg/mL were incubated in
t h ep r e s e n c eo fd i ﬀerent buﬀer solutions. Results are the aver-
age of two independent determinations using diﬀerent enzyme
preparations performing duplicate samples.
EffectoftemperatureandpHonlyso-PAFAT
activityofHMC
Experiments were carried out in order to found the
optimum conditions for the action of the enzyme. The
temperature—activityproﬁle was bell-shaped showing an
optimum at 37◦C. Three diﬀerent buﬀer solutions of var-
ious pH values, namely, 50mM acetic buﬀer pH 4–6,
50mM phosphate buﬀer pH 6–7, and Tris-HCl buﬀer pH
7–9, were utilized in order to investigate the dependence
of lyso-PAF AT activity on pH. The results are shown in
Figure 1. Lyso-PAF AT showed maximum activity at a pH
range between 7.2 and 7.4.
EffectofBSAonlyso-PAFATactivityofHMC
The eﬀect of BSA concentration on the activity of to-
tal membrane fractions of lyso-PAF AT was studied. As
shown in Figure 2, the maximum enzyme activity oc-
curred at 0.25mg/mL BSA ﬁnal concentration in reac-
tion mixture while 2.0mg/mL BSA reduced the activity
by 15% compared to the non-added control. The t test for
independent samples revealed that only 0.25mg/ml con-
centration of BSA gave statistical signiﬁcance diﬀerence
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Figure 2. Eﬀect of BSA concentration on lyso-PAF AT speciﬁc
activity of mesangial cells: TM fractions of HMC 0.23mg/mL
were incubated in the presence of diﬀerent concentrations of
B S A .R e s u l t sa r ee x p r e s s e da sp e r c e n tr e l a t e dt on o n - a d d e dc o n -
trol (100%). Results are the average of two independent deter-
minations using diﬀerent enzyme preparations performing du-
plicate samples. ∗P<. 05 versus control.
from the non-added control value (P = .049). Therefore,
0.25mg/mL ﬁnal concentration BSA was routinely used.
DependenceofPAFformationbyprotein
concentrationandincubationtime
The kinetics of PAF formation in relation to time and
the dependence of TM lyso-PAF AT activity on protein
concentration are shown in Figure 3. The total amount of
PAF formed at the end of each incubation time decreased
as protein concentration decreased (Figure 3a). A linear
relationship between the initial velocity and total protein
up to 0.05mg (0.25mg/mL) was found for 30-minute in-
cubation time (Figure 3b). In order to achieve the max-
imum yield of reaction 0.02–0.05mg (0.1–0.25mg/mL)
protein and 30-minute incubation time were routinely
used.
Effectofsubstratesconcentrationonlyso-PAFAT
activityandkineticparameters
The activity of lyso-PAF AT was determined at diﬀer-
entacetyl-CoAconcentrationsrangingfrom25to800µM
ataﬁxedconcentrationoflyso-PAF20µM.Theresultsre-
vealed that enzyme exhibited classical Michaelis-Menten
kinetics with respect to acetyl-CoA. When the concentra-
tion of lyso-PAF was varied between 2.5 and 100µMa ta
ﬁxed concentration of acetyl-CoA (200µM), the enzyme
followed simple saturation kinetics only up to 40µM.2005:5 (2005) Lyso-PAF Acetyltransferase of Human Mesangial Cells 267
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Figure 3.DependenceofPAFformationbyincubationtimeand
protein concentration: (a) time course of PAF production us-
ing 0.01, 0.02, 0.04mg total protein; (b) lyso-PAF AT activity as
a function of protein concentration at a ﬁxed incubation time
30 minutes. Experiments were performed with total membrane
fractions of HMC in the present of 20µM lyso-PAF and 200µM
acetyl-CoA. Results are the average of two independent determi-
nations using diﬀerent enzyme preparations performing dupli-
cate samples.
Higher concentrations of lyso-PAF resulted in a drop of
enzyme activity that was consistent with previously pub-
lished data [20, 27].
The kinetic parameters of the enzyme revealed from
these experiments are summarized in Table 2. The calcu-
lations for acetyl-CoA were made using nonlinear regres-
sion while the calculations for lyso-PAF were made using
linear regression (Lineweaver-Burk plot) since there was
no classical saturation curve.
Effectofdivalentcationsonlyso-PAFAT
activityofHMC
In order to study the eﬀect of divalent cations (Ca2+
and Mg2+) on the activity of lyso-PAF AT, 0.15mg/mL
of TM were incubated in the presence of various con-
centrations of CaCl2 and MgCl2. Low concentrations
Table 2. Kinetics parameters of lyso-PAF AT of total membrane
fractions of mesangial cells (n = 5).
KM,a p p V m a x ,a p p
(µM) (nmol/min/mg)
Lyso-PAFa 9.21 ±2.37 2.69 ±0.311
Acetyl-CoAb 71.2 ± 15.12 .83 ±0.252
aKinetic data were obtained from experiments shown in Figure 4. Initial
velocity data were analyzed by weighted ﬁts to the Michaelis-Menten
equation using linear regression for up to 40µMl y s o - P A Ff r o m
GraphPad Prism.
bKinetic data were obtained from experiments shown in Figure 4.
Initial velocity data were analyzed by weighted ﬁts to the
Mechaelis-Menten equation using nonlinear regression programme
adapted from GraphPad Prism.
Table 3. Eﬀect of divalent cations and chemicals on TM lyso-
PAF AT activity. Results are the average of two independent de-
terminations using diﬀerent enzyme preparations performing
duplicate samples.
Concentration Lyso-PAF AT speciﬁc
(M) activity (% of control)
MgCl2 10−4 101
MgCl2 10−3 94
MgCl2 10−2 81
CaCl2 10−5 94
CaCl2 10−4 104
CaCl2 10−3 108
CaCl2 10−2 54∗
EDTA 10−3 53∗
EDTA +CaCl2 10−3 +10 −2 70
∗P<. 05 versus control.
10−5–10−3 Mo fC a 2+ and Mg2+ did not inﬂuence the ac-
tivity of lyso- PAF AT while at higher concentration Ca2+
and Mg2+ (10−2 M) signiﬁcantly (P<. 05) reduced lyso-
P A FA Ta c t i v i t yb y4 6a n d1 9 % ,r e s p e c t i v e l y .W h e nT M
wereincubatedinthepresenceofethylene-diamino-tetra-
aceticacid(EDTA)10−3 Mtheenzymeactivitywassignif-
icantly (P<. 05) reduced by 47% while the addition of
Ca2+ 10−2 M partially overrode this reduction (P = .097)
(Table 3).
EFFECT OF CHEMICALS ON LYSO-PAF AT
ACTIVITY OF HMC
The eﬀect of various chemicals on lyso-PAF AT activ-
ity was also studied. The results are summarized in Figure
5. Sulfonyl-type serine protease inhibitors like Pefabloc
did not inﬂuence the activity of lyso-PAF AT. The pro-
tease inhibitor NaF (sodium ﬂuoride) slightly increases268 Elizabeth Fragopoulou et al 2005:5 (2005)
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Figure 4. Eﬀect of substrate concentration on lyso-PAF AT ac-
tivity: (a) activity of lyso-PAF AT as a function of acetyl-CoA at
ﬁxedconcentrationoflyso-PAF(20µM);(b)activityoflyso-PAF
AT as a function of lyso-PAF at ﬁxed concentration of acetyl-
CoA (200µM). Experiments were performed at total membrane
fractions using 0.23mg/mL protein in optimum conditions. Re-
sults represent the average ± SD from four independent deter-
minations using diﬀerent enzyme preparations performing du-
plicate samples.
the activity of the enzyme. Dithiothreitol (DTT) inhib-
itedenzymeactivitywithadose-dependentmanner.Since
DTT reduces disulﬁde bridges present in polypeptides
and proteins, this result indicates the presence of disul-
ﬁde bridges in the enzyme. Moreover, mercaptoethanol
had the same action with DTT supporting the existence
of disulﬁde groups (Figure 5). The t test for independent
samples revealed that only DTT at 5mM and mercap-
toethanol reduced signiﬁcant the activity of the enzyme
with P values .000 and .035, respectively.
PARTIAL PURIFICATION PROCEDURE
Solubilizationoftotalmembranes
An essential step in purifying the membrane enzyme
is to solubilize the enzyme from the membranes. For this
purpose, total membrane fractions from human kidney
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Figure 5. Eﬀect of chemicals on lyso-PAF AT activity: Total
membrane fractions of HMC 0.23mg/mL were incubated in
the presence of various chemicals. Results represent the average
two independent determinations using diﬀerent enzyme prepa-
rations performing duplicate samples and are expressed as per-
centrelatedtonon-addedcontrol(100%).(DTT;Dithiothreitol,
MeETOH; mercaptoethanol, NaF; sodium ﬂuoride) ∗P<. 05,
∗∗P<. 005 versus control.
tissue were used. All attempts to solubilize total mem-
brane fractions by sonication, in the absence of deter-
gents, were unsuccessful, therefore total membranes were
incubated with various solubilizing agents. Lyso-PAF AT
activity and the protein concentration were measured in
the supernatants and the pellets. A control in absence of
detergent was run concomitantly and the values were ex-
pressed as the % speciﬁc activity of lyso-PAF AT in the
supernatants of the solubilization procedure compared
to the non-added control (% non-added control). We
tried the ionic detergent sodium deoxycholate (0.2-0.4-
0.6-0.8-1.0%w.v), the nonionic detergents Triton X-100
(0.24-0.84-1.5%w.v), Tween 80 (0.2-0.4-0.8%w.v), the
steroid-baseddetergentsCHAPS(0.2-0.4-0.8%w.v),digi-
tonin (0.2-0.67-1.25 %w.v), and glycerol (3.2-6.4-16-32-
64%w.v). Although all detergents were successfully sol-
ubilized protein, glycerol was the only detergent able to
solubilize the enzyme without inactivating it. As shown in
Table 4, the higher the glycerol concentration, the more
eﬀective the enzyme solubilization. Therefore, routine
solubilization of TM fractions from human kidney tissue
and HMC was carried out with 30%w.w. glycerol (glyc-
erol/protein167w.w.)forroutineprocess.Higherglycerol
concentration made the removal of it diﬃcult in the next
steps of puriﬁcation. The kinetics parameters of the solu-
bilized fractions from HMC were also studied. These ex-
periments revealed KM,app and Vmax,app values of TM
and solubilized fractions 51.2µM, 2.96nmol/min/mg and
42.0µM, 2.05nmol/min/mg, respectively, with respect to
acetyl-CoAand11.3µM,3.17nmol/min/mgand12.4µM,
2.86nmol/min/mg, respectively, with respect to lyso-PAF.
Ionexchangechromatography-HPLC
In order to perform chromatographic separation, the
solubilized enzyme fractions had to be concentrated.
All attempts made to lyophilize the solubilized fractions2005:5 (2005) Lyso-PAF Acetyltransferase of Human Mesangial Cells 269
Table 4. Eﬀects of glycerol concentrations on the solubilization of lyso-PAF AT from membrane fraction of human kidney tissue.
Data represent the average of two experiments with duplicate determinations.
Glycerol Glycerol/Protein Protein in supernatant Speciﬁc activity
Yield (%) Puriﬁcation
(% w.v.) (w.w.) (% of total protein) (% of control)
3.2 20 15.9 56 6.82 0.45
6.4 40 18.7 71 8.77 0.49
16 100 16.78 290 18.0 1.12
32 200 17.7 396 24.1 1.43
64 400 26.5 740 61.1 2.42
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Figure 6. Ion exchange chromatography of solubilized fractions. Typical chromatographic puriﬁcation and activities of lyso-PAF AT
on fractions of (a) solubilized fractions of human kidney tissue and (b) solubilized fractions of HMC.
resulted in enzyme inactivation, for this reason, ultraﬁl-
tration using two compartment centrifuge tubes was car-
ried out as described in methods. The solubilized con-
centrated fractions of human kidney tissue and HMC
were subjected to HPLC separation under the conditions
described in methods. Lyso-PAF AT activity of human
kidney tissue was recovered in fractions 1, 2–4, and 10–
15 while the respective activity of the HMC in fractions
1–3 (Figure 6). The apparent KM,app and Vmax,app val-
ues with respect to lyso-PAF AT of HPLC active fractions270 Elizabeth Fragopoulou et al 2005:5 (2005)
from HMC were 19.2µM, 2.52nmol/min/mg. The yield
of this step was 10.2 and puriﬁcation 1.6.
Nondenaturingelectrophoresis
The solubilized fraction from human kidney tissue,
since there was not enough amount after the HPLC sep-
aration, and the active HPLC fractions 1–2 from mesan-
gial cells were subjected to gel-electrophoresis according
to methods. The activity of the lyso-PAF AT was present
in two gel fragments corresponding to apparent molecu-
lar weight values of 25–30kd of human kidney tissue, 75–
85kd of human kidney tissue, and 25–30kd and 65–80kd
of HMC (Figure 7). The calculation of apparent molecu-
lar weight was made based on the log MW = f(Rf)f u n c -
tion, which under the electrophoresis conditions was lin-
ear (y =− 1.045x +4 .97, R2 = 0.9875). The enzyme spe-
ciﬁcactivityoftheactivefragment(25–30kd)ofHMCaf-
ter nondenature PAGE was 2.78nmol/min/mg. The yield
of this step was 0.01 and puriﬁcation 1.9.
DISCUSSION
Platelet activating factor is a potent phospholipid me-
diator that is produced by a variety of tissues and cells
[1, 2]. The balance between PAF biosynthesis and degra-
dationdeterminesitslevels.Denovobiosynthesispathway
is thought to be responsible for the resting state lev-
els of PAF while the remodeling pathway is thought to
play a crucial role in inﬂammatory responses. Degrada-
tion of PAF occurs mainly with PAF-AH, which con-
verts it to inactive lyso-PAF. Although many studies exist
for PAF-AH, which has been cloned, there are not many
studies about biosynthetic enzymes of PAF metabolism.
Lyso-PAF AT is the main enzyme in remodeling pathway
and converts lyso-PAF to PAF using acetyl-CoA as acetyl
donor.
We have previously detected and characterized lyso-
PAF AT activity in cortex and medulla of human kidney
tissue [20]. In this study, we detected and characterized
lyso-PAF AT in human mesangial cells. Mesangial cells are
the main source of PAF in kidney and as far as we know
there is no any study on lyso-PAF AT in mesangial cells.
As previously described from others and us, the ac-
tivity of lyso-PAF AT has been detected on mitochondria
andmicrosomalfractions[20,21,27].Inordertohavethe
maximum enzyme amount, total membranes fractions
were used for the process. Total membranes lyso-PAF ac-
tivity was abolished when samples were pre-incubated
at 60◦C for 10 minutes. Maximum lyso-PAF AT activ-
ity was obtained at pH 7.4 and at incubation tempera-
ture 37◦C while dependence of enzyme activity on to-
tal protein showed linearity up to 50µg (250µg/mL). As-
says of acetyltransferase with lyso-PAF as a substrate are
routinely performed in the presence of BSA, which binds
PAF as it is formed [34]. It has been reported that 0.75–
2.5mg/mL BSA in the presence of low protein concen-
tration (10–60µg/mL) activates lyso-PAF AT while higher
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Figure 7. Native-PAGE electrophoresis: Lyso-PAF AT speciﬁc
activities on native PAGE electrophoresis of solubilized fractions
of human kidney tissue (-◦-) and active HPLC fractions 1, 2 of
mesangial cells (-•-). The Log MW of standard proteins versus
mobility was linear. Lines M, 1, and 2 represent the part of the
gel stained by Coomassie Blue from molecular markers, human
kidney tissue, and HMC, respectively.
protein concentration (200µg/mL) showed no signiﬁcant
eﬀect. In the present study 230µg/mL of protein was used
and BSA signiﬁcantly increased (P<. 05) the activity of
lyso-PAF AT at 0.25mg/mL while at higher concentration
caused a slightly not signiﬁcant reduction of lyso-PAF AT
activity.Thisresultiswithagreementwithpreviousreport
that demonstrating that the membranes could be also ef-
fective in binding PAF [32].
Regarding the eﬀect of substrates on lyso-PAF AT
activity the experiments revealed that lyso-PAF AT fol-
lowed typical Michaelis-Menten kinetic proﬁle with re-
spect to acetyl-CoA while followed simple saturation ki-
netics with respect to lyso-PAF only up to 50µM. Higher
concentrations of lyso-PAF resulted in a drop of enzyme
a c t i v i t y .T h i si sc o n s i s t e n tw i t hp r e v i o u sd a t af r o mo u r
laboratory and others and probably due to detergent ef-
fect of lysophospholipids [20, 37].
Exogenous addition of the divalent cations Ca2+and
Mg2+ (10−2 M) at high concentrations reduced the en-
zyme activity. EDTA inhibited the lyso-PAF AT activity
and this inhibition is partially reversed by the addition of
Ca2+.I ts e e m st h a tl y s o - P A FA Tr e q u i r e das p e c i ﬁ cc o n -
centration of Ca+2 for its activation and that higher or
lower concentration resulting in inactivation. It has been
reported that Ca2+ is required for the lyso-PAF activity
[20, 38] but others have been indicated otherwise [16].
DTT and mercaptoethanol signiﬁcantly (P<. 000 and
P<. 05, respectively) inhibited lyso-PAF acetyltranserase
indicating that there are disulﬁde bridges present in the
enzyme. Pefabloc had no signiﬁcant eﬀect on the enzyme
actionsupportingtheabsenceofserine(s)intheactivesite
oftheenzyme.Inaddition,pefablocisaPAFAHinhibitor
and it seems that the possible presence of PAF AH in the
assay did not inﬂuence PAF formation, which is in agree-
ment with our previous results [20].
Lyso-PAF AT is a very labile enzyme that is very sensi-
tivetodetergents.Solubilizationoftheenzymefromother
t i s s u e swi t hs o d i u md e o x y c h o l a t ea n dgl y c e r o lh a sa l r e a d y
been reported [22, 23, 24] .I nt h ep r e s e n ts t u d y ,m o s to f
the common detergents used resulted in total inactivation2005:5 (2005) Lyso-PAF Acetyltransferase of Human Mesangial Cells 271
of the enzyme and only glycerol managed to solubilize the
enzyme without inactivation. Concentration of 32%w.w
glycerol had a 24% yield in the solubilization of hu-
man kidney tissue and human mesangial cells lyso-PAF
AT. Furthermore, an attempt was made to purify lyso-
PAF AT from human kidney tissue and human mesangial
cells. The partial puriﬁcation procedure consisted of only
two steps, namely, anion exchange chromatography and
native-PAGE electophoresis, since the limited amount of
enzyme preparation along with the low recovery rate, es-
pecially in human kidney tissues, prevented us from uti-
lizing a more extensive puriﬁcation process. Native-PAGE
electrophoresis of the partially puriﬁed enzyme from hu-
man kidney tissue and HMC resulted in two active frac-
tions in both cases of approximately 25–30kd and 75–
85kd molecular weight. A 30kd band of lyso-PAF AT
activity from rat spleens after nondenaturing conditions
electrophoresis has been reported [24]. More investiga-
tion is required in order to explain if the one band is due
to an enzyme dimmer formation or to another isoenzyme
or more possible to an enzyme comlex with membrane
fractions.
Thesedatademonstratethatlyso-PAFacetyltranferase
activity is present in human mesangial cells and estab-
lished the biochemical properties of this enzyme for the
ﬁrst time in human mesangial cells. Concerning our pre-
vious data, lyso-PAF AT of mesangial cells seems to have
similar properties with lyso-PAF AT characterized in hu-
man kidney tissue (medulla and cortex), supporting that
mesangial cells are the primary source of PAF in the kid-
ney. Moreover, solubilization and partial puriﬁcation of
human kidney tissue and mesangial cells lyso-PAF AT
were achieved.
PAF production in kidney, mainly by mesangial cells,
is involved in the pathogenesis of renal damage. The char-
acterization of lyso-PAF AT activity in human mesangial
cells enables the further investigation of lyso-PAF AT reg-
ulatory mechanisms and therefore PAF production under
inﬂammatory conditions.
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